Delcath Systems Inc (DCTH)

Currency in USD
16.960
-0.150(-0.88%)
Real-time Data·
DCTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.86517.250
52 wk Range
8.12017.420
Key Statistics
Prev. Close
17.11
Open
17.25
Day's Range
16.865-17.25
52 wk Range
8.12-17.42
Volume
51.61K
Average Volume (3m)
560.3K
1-Year Change
52.8353%
Book Value / Share
3.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DCTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.000
Upside
+41.51%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Delcath Systems Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.000
(+41.51% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy18.00+6.13%20.00MaintainFeb 27, 2026
Clear Street
Buy27.00+59.20%29.00MaintainFeb 26, 2026
BTIG
Buy19.00+12.03%23.00MaintainFeb 26, 2026
Stephens
Buy18.00+6.13%25.00MaintainNov 05, 2025
Craig-Hallum
Buy20.00+17.92%24.00MaintainOct 21, 2025

Delcath Systems Inc Earnings Call Summary for Q2/2026

  • Delcath Q2 2026 revenue hit $29.1M, beating $26.6M forecast by 9.4%; shares surged 16.98% to $14.775 in premarket trading.
  • HEPZATO KIT sales rose 21% YoY to $27.1M, comprising 93% of revenue; gross margin improved to 90% from 86% prior year.
  • Company raised FY 2026 revenue guidance to $104M-$108M, expecting 28% HEPZATO volume growth with positive adjusted EBITDA.
  • Delcath expanded to 31 active treatment centers, targeting 37 by year-end; 80% are NCI Comprehensive Cancer Centers.
  • 340B pricing pressured ASP to $170K-$173K from $185K; clinical trials in breast and colorectal cancer face enrollment delays.
Last Updated: 2026-08-06, 09:48 a/m
Read Full Transcript

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
0.07 / -0.10
Revenue / Forecast
29.13M / 26.6M
EPS Revisions
Last 90 days

DCTH Income Statement

Compare DCTH to Peers and Sector

Metrics to compare
DCTH
Peers
Sector
Relationship
P/E Ratio
1,116.0x−2.7x−0.3x
PEG Ratio
−15.53−0.220.00
Price/Book
4.9x3.6x2.6x
Price / LTM Sales
6.2x2.6x3.1x
Upside (Analyst Target)
28.6%116.7%48.3%
Fair Value Upside
Unlock8.2%6.7%Unlock

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
5.82M16.86%99.60M
Other Institutional Investors
17.05M49.38%291.69M
Public Companies & Retail Investors
11.65M33.75%199.37M
Total
34.52M100.00%590.66M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Rosalind Opportunities Fund I L.P10.23%3,530,21560,402
Rosalind Advisors, Inc.9.56%3,300,38956,470

People Also Watch

168.62
BR
-0.39%
39.15
HRMY
-1.56%
191.87
NTRS
+0.28%
6.08
ASPN
-1.14%

FAQ

What Is the Delcath Systems (DCTH) Stock Price Today?

The Delcath Systems stock price today is 16.960 USD.

What Stock Exchange Does Delcath Systems Trade On?

Delcath Systems is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Delcath Systems?

The stock symbol for Delcath Systems is "DCTH."

What Is the Delcath Systems Market Cap?

As of today, Delcath Systems market cap is 588.490M USD.

What Is Delcath Systems's Earnings Per Share (TTM)?

The Delcath Systems EPS (TTM) is 0.015.

When Is the Next Delcath Systems Earnings Date?

Delcath Systems will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is DCTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Delcath Systems Stock Split?

Delcath Systems has split 5 times.

How Many Employees Does Delcath Systems Have?

Delcath Systems has 156 employees.

What is the current trading status of Delcath Systems (DCTH)?

As of Aug 13, 2026, Delcath Systems (DCTH) is trading at a price of 16.960 USD, with a previous close of 17.110 USD. The stock has fluctuated within a day range of 16.865 USD to 17.250 USD, while its 52-week range spans from 8.120 USD to 17.420 USD.

What Is Delcath Systems (DCTH) Price Target According to Analysts?

The average 12-month price target for Delcath Systems is 24.000 USD, with a high estimate of 32 USD and a low estimate of 21 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +41.51% Upside potential.

What Is the DCTH Premarket Price?

DCTH's last pre-market stock price is 17.058 USD. The pre-market share volume is 510.000, and the stock has decreased by -0.052, or -0.300%.

What Is the DCTH After Hours Price?

DCTH's last after hours stock price is 17.620 USD, the stock has decreased by 0.510, or 2.980%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.